Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909423 | 0.90 | CCR1 (0.50) | CCR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL3232118 | 0.88 | CCR1 (0.39) | CCR1CHRM2CHRM1CHRM3POLB | |
| SCHEMBL3489152 | 0.83 | EPHX1 (0.47) | CHRM1POLBSIGMAR1KDM4E | |
| SCHEMBL5555057 | 0.82 | CCR1 (0.60) | CCR1CHRM2CHRM1CHRM3 | |
| SCHEMBL22208127 | 0.81 | POLB (0.46) | POLBSIGMAR1KDM4EHSD17B10 | |
| SCHEMBL15130431 | 0.80 | CHRM5 (0.48) | CCR1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL15191011 | 0.80 | CHRM5 (0.48) | CCR1CHRM2CHRM1CHRM3KDM4E | |
| SCHEMBL3489007 | 0.79 | DRD2 (0.55) | — | |
| SCHEMBL3263447 | 0.79 | HTT (0.41) | POLBSIGMAR1KDM4ETDP1PARP1 | |
| SCHEMBL4119281 | 0.79 | CHRM5 (0.52) | CCR1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075973-A1 | POLO-LIKE KINASE INHIBITORS | PLK2, PLK4, PLK1 | CCR1 4556/4885CHRM2 4880/4885CHRM1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.